Erudio Healtherudio.com
Clinical trial · no report yet · Phase 1
COSMIC-021
Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
- NCT03170960 ↗
- Active, not recruiting
- Exelixis
- Deep
We haven't built an HCP commentary report on COSMIC-021 (cabozantinib and atezolizumab in Urothelial Carcinoma) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on COSMIC-021 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 36 | |
| Podcasts | 12 | |
| YouTube | 7 | |
| X videos | 1 |
The trial
ClinicalTrials.gov- Official title
- A Phase 1b Dose-Escalation Study of Cabozantinib (XL184) Administered Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
- Phase
- Phase 1
- Status
- Active, not recruiting
- Conditions
- Urothelial Carcinoma; Renal Cell Carcinoma; Non-Small Cell Lung Cancer; Castration-resistant Prostate Cancer; Triple Negative Breast Cancer; Ovarian Cancer; Endometrial Cancer; Hepatocellular Carcinoma; Gastric Cancer; Gastroesophageal Junction Adenocarcinoma; Colorectal Cancer; Head and Neck Cancer; Differentiated Thyroid Cancer; Lower Esophageal Cancer
- Interventions
- cabozantinib; atezolizumab; cabozantinib; cabozantinib
- Arms
- Dose Escalation · Experimental
- Expansion Cohort 1 · Experimental
- Expansion Cohort 2 · Experimental
- Expansion Cohort 3 · Experimental
- Expansion Cohort 4 · Experimental
- Expansion Cohort 5 · Experimental
- Expansion Cohort 6 · Experimental
- Expansion Cohort 7 · Experimental
- Expansion Cohort 8 · Experimental
- Expansion Cohort 9 · Experimental
- Expansion Cohort 10 · Experimental
- Expansion Cohort 11 · Experimental
- Expansion Cohort 12 · Experimental
- Expansion Cohort 13 · Experimental
- Expansion Cohort 14 · Experimental
- Expansion Cohort 15 · Experimental
- Expansion Cohort 16 · Experimental
- Expansion Cohort 17 · Experimental
- Expansion Cohort 18 · Experimental
- Expansion Cohort 19 (SAC) · Experimental
- Expansion Cohort 20 (SAC) · Experimental
- Expansion Cohort 21 (SAC) · Experimental
- Expansion Cohort 22 (SAA) · Experimental
- Expansion Cohort 23 · Experimental
- Expansion Cohort 24 · Experimental
- Enrollment
- 914
- Primary outcomes
- Dose Escalation: MTD/Recommended Dose
- Dose Expansion: ORR
- Sponsor
- Exelixis
- Start
- Sep 5, 2017
- Primary completion
- Feb 21, 2023
- Results posted
- No
- Registry record
- NCT03170960 · updated Oct 1, 2026
Publications
linked from the registry- Pal SK, Loriot Y, Necchi A, Singh P, Castellano D, Pagliaro L, Suarez C, McGregor BA, Vaishampayan UN, Hauke RJ, Powles T, Van Herpen CML, Courtney KD, Dreicer R, Sudhagoni R, Schwickart M, Andrianova S, Agarwal N. COSMIC-021 Phase Ib Study of Cabozantinib Plus Atezolizumab: Results from the Locally Advanced or Metastatic Urothelial Carcinoma Cohorts. J Clin Oncol. 2025 May 10;43(14):1650-1662. doi: 10.1200/JCO-24-01675. Epub 2025 Feb 18. PubMed 39965176
- Li D, Loriot Y, Burgoyne AM, Cleary JM, Santoro A, Lin D, Aix SP, Garrido-Laguna I, Sudhagoni R, Guo X, Andrianova S, Paulson S. Cabozantinib plus atezolizumab in previously untreated advanced hepatocellular carcinoma and previously treated gastric cancer and gastroesophageal junction adenocarcinoma: results from two expansion cohorts of a multicentre, open-label, phase 1b trial (COSMIC-021). EClinicalMedicine. 2023 Dec 21;67:102376. doi: 10.1016/j.eclinm.2023.102376. eCollection 2024 Jan. PubMed 38204489
- Agarwal N, McGregor B, Maughan BL, Dorff TB, Kelly W, Fang B, McKay RR, Singh P, Pagliaro L, Dreicer R, Srinivas S, Loriot Y, Vaishampayan U, Goel S, Curran D, Panneerselvam A, Schwickart M, Choueiri TK, Pal S. Cabozantinib in combination with atezolizumab in patients with metastatic castration-resistant prostate cancer: results from an expansion cohort of a multicentre, open-label, phase 1b trial (COSMIC-021). Lancet Oncol. 2022 Jul;23(7):899-909. doi: 10.1016/S1470-2045(22)00278-9. Epub 2022 Jun 9. PubMed 35690072
- Pal SK, McGregor B, Suarez C, Tsao CK, Kelly W, Vaishampayan U, Pagliaro L, Maughan BL, Loriot Y, Castellano D, Srinivas S, McKay RR, Dreicer R, Hutson T, Dubey S, Werneke S, Panneerselvam A, Curran D, Scheffold C, Choueiri TK, Agarwal N. Cabozantinib in Combination With Atezolizumab for Advanced Renal Cell Carcinoma: Results From the COSMIC-021 Study. J Clin Oncol. 2021 Nov 20;39(33):3725-3736. doi: 10.1200/JCO.21.00939. Epub 2021 Sep 7. PubMed 34491815